胃肠腺癌中耐药基因的表达及临床意义  

Expression and significance of resistance genes in the gastrointestinal adenocarcinoma

作　　者：怀建国[1] 蒋艳[1] 杨小苗[1] 徐曼[1] 朱燕燕[1] 申成香 司有谊 汪谟庆 

机构地区：[1]安徽省芜湖市第一人民医院病理科

出　　处：《中国临床药理学与治疗学》2014年第4期393-397,共5页Chinese Journal of Clinical Pharmacology and Therapeutics

基　　金：芜湖市科技局科技计划项目(2011卫生6-2)

摘　　要：目的:探讨TopoⅡ、P-gp、MRP、LRP、TS等耐药基因在胃肠腺癌中的表达及意义,以期为临床化疗药物的选择提供理论依据。方法:选择胃肠腺癌各25例病例为实验组,各病例癌旁组织作为对照组,应用病理图像分析、免疫组化S-P法并文献复习。结果:TopoⅡ在中分化腺癌组织中的表达低于低分化腺癌组织。P-gp、MRP1、MRP3、TS、GST-π、β-TubulinⅢ在不同类型的胃癌和肠癌中均有不同程度的表达,在癌组织中的阳性表达率均高于在癌旁组织中的表达。MRP和β-TubulinⅢ在黏液腺癌中表达率较高,LRP在胃肠腺癌很少表达。结论:TopoⅡ是肿瘤药物靶点之一,阳性率与用相应化疗药效果正相关。联合检测P-gp、MRP1、MRP3、TS、GST-π、β-TubulinⅢ在胃肠腺癌中的表达对临床化疗药物选择有一定参考意义。本组所选择的基因在肠癌与在胃癌中的表达相似,两者无明显差别。AIM To investigate the expression and significance of Topo Ⅱ, P-gp, MRP, LRP, TS and other resistance genes in the gastrointestinal adenocarcinoma , in order to provide a theoretical basis for the choice of chemotherapeutic drugs . METHODSThe study included 25 cases of gastrointestinal cancer cases as experimental group , each case adjacent tissues as a control group ,we detected with pathology image analysis , immunohistochemistry SP method and literature review. RESULTS： Topo Ⅱpositive rate in moderately differentiated adenocarcinoma tissues was higher than poorly differentiated adenocarcinoma. P-gp, MRP1, MRP3, TS, GST-π, β-Tubulin Ⅲ in different types of gastric cancer and colorectal cancer have different levels of expression in cancer tissues were higher than in the adjacent tissues. MRP and β-Tubulin Ⅲ in Mucinous adenocarcinoma have higher rate. LRP rarely expressed in the gastrointestinal adenocarcinoma. CONCLUSION： Topo Ⅱ cancer drug target is one of the positive rate of the corresponding positive effects of chemotherapy drugs. Combined detection of P-gp, MRP1, MRP3, TS, GST-π, β-Tubulin Ⅲ in the gastrointestinal adenocarcinoma of clinical medicine has a certain reference value. The group of selected genes in colorectal and gastric carcinoma were in a similar, There was no significant difference.

关 键 词：胃腺癌 结肠腺癌 TopoⅡ 耐药基因 免疫组化 

分 类 号：R735[医药卫生—肿瘤]